Regeneron Pharmaceuticals... (REGN)
NASDAQ: REGN
· Real-Time Price · USD
594.50
9.51 (1.63%)
At close: May 16, 2025, 3:59 PM
595.00
0.08%
After-hours: May 16, 2025, 07:59 PM EDT
Regeneron Pharmaceuticals Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
|---|---|---|---|---|---|---|---|
| Collaboration Revenue Revenue | 6.06B | 5.5B | 2.06B | 281.2M | 5.57B | 4.83B | 4.11B |
| Collaboration Revenue Revenue Growth | +10.08% | +167.35% | +632.01% | -94.95% | +15.17% | +17.73% | n/a |
| Product and Service, Other Revenue | 515M | 536.1M | 365.1M | 12.12B | n/a | n/a | n/a |
| Product and Service, Other Revenue Growth | -3.94% | +46.84% | -96.99% | n/a | n/a | n/a | n/a |
| Product Revenue | 7.63B | 7.08B | 6.89B | n/a | n/a | n/a | n/a |
| Product Revenue Growth | +7.79% | +2.67% | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 633M | 792.2M | 714.4M | 758.8M | 689M | 737.7M | 640.5M | 652M | 601.1M | 660.5M | 529.1M | 476.3M | 450M | 559.6M | 445M | 414.7M | 405.6M | 303.5M | 326.9M | 348.3M | 367.3M | 586.8M | 419.9M | 417.3M | 410.8M | 491.3M | 369.23M | 364.88M | 330.77M | 409.91M | 306.77M | 306.91M | 296.85M | 325.94M | 270.05M | 292.04M | 289.68M | 294.95M | 209.99M | 174.59M | 158.99M |
| Selling, General, and Administrative Revenue Growth | -20.10% | +10.89% | -5.85% | +10.13% | -6.60% | +15.18% | -1.76% | +8.47% | -8.99% | +24.83% | +11.09% | +5.84% | -19.59% | +25.75% | +7.31% | +2.24% | +33.64% | -7.16% | -6.14% | -5.17% | -37.41% | +39.75% | +0.62% | +1.58% | -16.39% | +33.06% | +1.19% | +10.31% | -19.31% | +33.62% | -0.05% | +3.39% | -8.93% | +20.70% | -7.53% | +0.82% | -1.79% | +40.46% | +20.28% | +9.81% | n/a |
| Research and Development Revenue | 1.34B | 1.41B | 1.27B | 1.08B | 1.13B | 1.18B | 1.08B | 1.09B | 1.1B | 1.04B | 911.3M | 794.3M | 843.8M | 785.6M | 665.4M | 714.2M | 742.9M | 744.5M | 684.6M | 722M | 583.9M | 683.1M | 663.4M | 1.05B | 641.8M | 601.2M | 556.97M | 529.29M | 498.59M | 527.98M | 529.75M | 509.98M | 507.44M | 479.21M | 543.05M | 559.93M | 470.11M | 461.21M | 425.92M | 390.33M | 343.11M |
| Research and Development Revenue Growth | -5.13% | +11.06% | +17.81% | -4.85% | -3.64% | +9.48% | -0.92% | -1.44% | +5.57% | +14.46% | +14.73% | -5.87% | +7.41% | +18.06% | -6.83% | -3.86% | -0.21% | +8.75% | -5.18% | +23.65% | -14.52% | +2.97% | -36.72% | +63.34% | +6.75% | +7.94% | +5.23% | +6.16% | -5.57% | -0.33% | +3.88% | +0.50% | +5.89% | -11.76% | -3.02% | +19.11% | +1.93% | +8.28% | +9.12% | +13.76% | n/a |